Ferring Presents Phase III Data for a Controlled Release Misoprostol Vaginal Delivery System for Labour Induction at the First European Congress on Intrapartum Care

New Drug Approvals




Misoprostol is a synthetic prostaglandin E1 (PGE1) analog that is used for the prevention of nonsteroidal anti-inflammatory drug (NSAID) induced gastric ulcers, to treat missed miscarriage, to induce labor, and as an abortifacient. The latter use is controversial in theUnited States. Misoprostol was invented and marketed by G.D. Searle & Company (nowPfizer) under the trade name Cytotec, but other brand-name and generic formulations are now available as well.

Misoprostol is approved for use in the prevention of NSAID induced gastric ulcers. It acts upon gastric parietal cells, inhibiting the secretion of gastric acid via G-protein coupled receptor mediated inhibition of adenylate cyclase, which leads to decreased intracellularcyclic AMP levels and decreased proton pump activity at the apical surface of the parietal cell. Because

View original post

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

New Drug Approvals


Merck , known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment of Parkinson’s disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo…..read more at



Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson’s disease.Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013

View original post

Human medicines European Public Assessment Report EPAR : Rilutek, riluzole, Revision: 17,

New Drug Approvals

Riluzole is a drug used to treat amyotrophic lateral sclerosis. It delays the onset ofventilator-dependence or tracheostomy in selected patients and may increase survival by approximately 3–5 months

It is marketed by Sanofi-Aventis with the brand name Rilutek.

read all at


View original post

Ferring Pharmaceuticals begins phase III trials of elobixibat, a new investigational compound for chronic idiopathic constipation

New Drug Approvals

File:Elobixibat skeletal.svg


Ferring Pharmaceuticals begins phase III trials of elobixibat, a new investigational compound for chronic idiopathic constipation


Ferring Pharmaceuticals today MAY 2, 2013, announced it has initiated enrolment of patients in two phase III clinical trials of the investigational compound elobixibat for the treatment of chronic idiopathic constipation (CIC), a common gastrointestinal disorder affecting approximately 14% of the general population1. The two studies, Echo 1 and Echo 2, will be conducted at close to 200 sites worldwide and will enroll nearly 1700 patients. The studies aim to demonstrate the efficacy and safety of repeated daily doses of elobixibat against placebo over a period of up to 26 weeks.

Elobixibat is a first-in-class compound with a novel physiological mechanism of action. It acts locally in the gut with minimal systemic exposure to enhance the amount of luminal bile acids in the colon by a partial inhibition of the…

View original post 395 more words

Turning Off Cancer’s “Master Regulator”

New Drug Approvals

Fig 1.

Researchers have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The Johns Hopkins researchers hope that this “master regulator” gene may be the key to developing a new treatment for tumors resistant to current drugs………from……………..


read all at


View original post